Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study

Not Applicable

Completed

• Conditions: Osteogenesis Imperfecta

• Registration Number: NCT00187018
• Lead Sponsor: St. Jude Children's Research Hospital

Brief Summary

Osteogenesis imperfecta (OI) is a genetic disease for which there is currently no known cure. OI causes the osteoblasts (bone-forming cells in the body) to grow poorly, which slows the growth of children with the disease and causes their bones to bend and break easily. Some forms of osteogenesis imperfecta may cause severe disability and even death. In previous research studies performed at St. Jude, it was found that children treated with bone marrow transplant (infusion of healthy immature blood-forming cells) began to grow faster, had more minerals (material that helps make the bones strong) in their bones, and broke their bones less often than before the bone marrow transplant. Several months after the bone marrow transplant however, body growth once again began to slow down. In this research study, children with osteogenesis imperfecta will receive another infusion of bone marrow cells but without any chemotherapy. The marrow cells will come from the same bone marrow donor as their previous bone marrow transplant. It is hoped that by removing the CD3+ cells (a type of white blood cells that attack other cells that are not like themselves) from the donated bone marrow, the subject's body will be infused quite safely and that body growth and bone strength will increase. The CD3+ cells will be removed from the donor bone marrow by use of a machine called the CliniMACS System. This machine has not been approved for use in the United States by the Food and Drug Administration (FDA). The use of this device is considered experimental.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-16
• Status Verified: 2007-05
• Primary Completion: 2007-08
• Study Completion: 2007-08
• Last Update Submitted: 2015-03-03
• Last Update Posted: 2015-03-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

• Must have been previously enrolled on TOIT protocol at St. Jude Children's Research Hospital
• Must have original bone marrow donor available and willing to participate as a donor
• Normal liver function
• Hemoglobin >10gm/dl

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To find out if there is any effect on the growth rate of children with osteogenesis imperfecta who receive donor bone marrow which has had CD3+ cells removed
To find out the effects (good and bad) of bone marrow cell infusions using donor bone marrow that has had CD3+ cells removed
To find out if there is any effect on the total bone mineral content of children with OI
who receive donor bone marrow which has had CD3+ cells removed

Secondary Outcome Measures

Name	Time	Method
To find out the effect of the CD3 washed-out marrow cell therapy on the growth rate of the children

Trial Locations

Locations (1)

St. Jude Children's Research Hospital; 🇺🇸 Memphis, Tennessee, United States